Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study
Author:
Nielsen Peter Brønnum12ORCID, Melgaard Line12, Overvad Thure Filskov3ORCID, Jensen Martin1ORCID, Larsen Torben Bjerregaard12, Lip Gregory Y.H.24ORCID, Veltkamp Roland, Harvey Kirsten H, Korompoki Eleni, D’Anna Lucio, Halse Omid, Hügen Klemens, Malzahn Uwe, Ullmann Sabine, Schuhmann Carolin, Todd Gabriele Putz, Brinz Hannes, Heuschmann Peter U., Haas Kirsten, Rücker Viktoria, Enzinger Christian, Ropele Stefan, Pinter Daniela, Haidegger Melanie, Gattringer Thomas, Fandler-Höfler Simon, Wolfe Charles D. A., Wang Yanzhong, Wafa Hatem A., Montaner Joan, Palà Elena, Debette Stéphanie, Sibon Igor, Renou Pauline, Lachaize Morgane, Milan Léa, Heyvang Nathalie, Ledure Sylvain, Michel Pascale, Graziani Mara, Marchini Laura, Caso Valeria, Horstmann Solveigh, Purrucker Jan, Ringleb Peter, Haffa Mariam, Hoppe-Tichy Torsten, Haefeli Walter E., Seidling Hanna M., Burhenne Jürgen, Foerster Kathrin I., Lane Deirdre A, Ivany Elena, Lotto Robyn
Affiliation:
1. Department of Cardiology (P.B.N., L.M., M.J. T.B.L.), Aalborg University Hospital, Denmark. 2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark (P.B.N., L.M., T.B.L, G.Y.H.L.). 3. Department of Clinical Pharmacology (T.F.O.), Aalborg University Hospital, Denmark. 4. Liverpool Centre for Cardiovascular Sciences, University Liverpool and Liverpool Heart & Chest Hospital, United Kingdom (G.Y.H.L.).
Abstract
Background:
In patients with intracerebral hemorrhage (ICH) and prevalent atrial fibrillation (AF), the optimal stroke prevention strategy is unclear. We sought to estimate the risk of cerebrovascular events among ICH survivors with AF.
Methods:
We used the Danish Stroke Registry to identify patients with incident ICH and prevalent AF between 2003 and 2018. Key inclusion/exclusion criteria of the PRESTIGE-AF (Prevention of Stroke in Intracerebral hemorrhage Survivors With Atrial Fibrillation) trial were applied. Cumulative incidence of recurrent ICH, cerebrovascular ischemic event, and all-cause death were investigated after one year.
Results:
A total of 1885 patients (median age 80.0 years; 47.6% females) were included in the study. We observed 191 cerebrovascular events and 650 all-cause deaths, and more cerebrovascular ischemic events (N=63) than recurrent ICH events (N=40). Risks of recurrent ICH, cerebrovascular ischemic event, and all-cause death were 1.5%, 3.2%, and 30.3%, respectively, among patients not exposed to OAC during follow-up. The cumulative incidences were 2.8% for recurrent ICH, 3.2% for cerebrovascular ischemic events, and 22.0% for all-cause death among patients initiating/resuming OAC during follow-up.
Conclusions:
We observed a high risk of cerebrovascular ischemic events and a very high risk of all-cause death at one year after the incident ICH. The results of ongoing clinical trials are warranted to determine optimal stroke prevention treatment among ICH survivors with concomitant AF.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|